Navigation Links
Questcor Pharmaceuticals Selects BDO USA as its Auditor
Date:3/4/2011

ANAHEIM, Calif., March 4, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) has completed a formal selection process and appointed BDO USA, LLP ("BDO") as its independent, registered public accounting firm for the auditing of Questcor's consolidated financial statements.  Questcor has selected BDO to replace Odenberg Ullakko Muranishi & Co. LLP ("OUM") as its independent registered public accounting firm.

"As we continue our strategy to grow through increased sales of Acthar, we believe that BDO will provide Questcor and its stakeholders with the highest levels of assurance services for our financial accounting, reporting and compliance requirements," said Don M. Bailey, President and CEO of Questcor. "We appreciate the efforts and professionalism of the team at Odenberg Ullakko Muranishi & Co. during the past 6 years."

During the period in which OUM was engaged with Questcor, there were no disagreements between OUM and Questcor on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure. If there had been such disagreements, OUM would have been compelled to disclose the nature of the disagreements with its reports. The reports of OUM on the consolidated financial statements of the Company did not contain any adverse opinion or disclaimer of opinion. These reports have not been qualified or modified as to uncertainty, audit scope or accounting principles.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from two indications: the treatment of acute exacerbations of multiple sclerosis in adults and the treatment of infantile spasms in children under two years of age.  Questcor is also implementing plans to commercialize Acthar for use in treating nephrotic syndrome, another on-label indication. Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Reports 2010 Financial Results
2. Questcor to Report Fourth Quarter and Full Year 2010 Earnings and Conduct Conference Call on February 23, 2011
3. Questcor Pharmaceuticals Reports Strong Finish to 2010
4. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2011
5. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
6. Questcor to Present at the Maxim Group Growth Conference
7. Questcor Reports Third Quarter 2010 Results
8. Questcor to Present at the 21st Annual Oppenheimer Healthcare Conference
9. Questcor Teams With Child Neurology Foundation (CNF) to Fund Infantile Spasms Scientific Research
10. Questcor and Child Neurology Foundation Support the 2nd Annual Infantile Spasms (IS) Awareness Week
11. Questcor to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... BOSTON , March 27, 2017 ... pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), ... commercialization of innovative therapies based upon tetracycline chemistry, ... sarecycline for the treatment of moderate to severe ... Sarecycline is a once-daily, oral, narrow spectrum tetracycline-derived ...
(Date:3/27/2017)... 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that ... Bisaro as Impax,s President and Chief Executive Officer ... 27, 2017. Mr. Bisaro will succeed J. Kevin ... Chief Executive Officer since December of 2016. ... experience, Mr. Bisaro, 56, is an accomplished global business ...
(Date:3/27/2017)... March 27, 2017  PhaseRx, Inc. (NASDAQ: PZRX), ... inherited liver diseases in children, today reported financial ... ended December 31, 2016 and provided an update ... continued to make progress during the fourth quarter ... from our non-human primate safety study, and with our ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... ... still in shock after receiving a $2,500 Academic Award from California Casualty . “This ... She thinks the coming week is going to be a very joyful for her classroom. ... students.” , The award will allow the 4th grade teacher at Tumwater Hill Elementary School ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy ... resolve the pending litigation between itself and 1800 Vending DBA Healthy You Vending. ... “I am thrilled to announce that we have now reached a settlement agreement ...
(Date:3/26/2017)... (PRWEB) , ... March 26, 2017 , ... ... worldwide to receive the RealSelf 100 Award, a prestigious award honoring the top ... procedures and to find and connect with doctors and clinics. , In 2016, ...
(Date:3/24/2017)... York, NY (PRWEB) , ... March 24, 2017 ... ... campaign: “Fighting Infection,” which will spark a conversation on the current obstacles facing ... the number of completely preventable deaths caused by these infections. , The ...
(Date:3/24/2017)... ... March 24, 2017 , ... Texas Physical Therapy Specialists (TexPTS) is ... 9618 Huebner Road. The clinic is the group’s 7th location in San Antonio and ... Higgins, PT, will provide care from the clinic, which opened March 22, 2017. ...
Breaking Medicine News(10 mins):